37000v威尼斯(中國股份)有限公司-官方網站歡迎您 /oxford-biotherapeutics-expands-strategic-collaboration-with-wuxi-biologics-and-licenses-wuxibody-platform-for-five-bispecific-antibody-programs-for-up-to-450-million/ 提供端到端一站式解决方案 Thu, 15 Jul 2021 03:07:55 +0000 hourly 1